Urine Chemistry Reveals Hidden Signatures of Parkinson’s Disease

Scientists have uncovered a detailed chemical fingerprint of Parkinson’s disease hidden in one of the most routinely collected and least invasive fluids in medicine: urine. In a new study published in npj Parkinson’s Disease, researchers mapped the submetabolome of dansylated urinary amines and phenols, showing that the small nitrogen- and phenol-containing molecules excreted by patients with Parkinson’s disease form a distinctive pattern that can separate them from healthy individuals with striking clarity. The work, which appeared online in November 2026, offers a fresh window into the metabolic upheaval that accompanies the neurodegenerative disorder and points toward a practical route to biomarkers that could one day support earlier diagnosis and better monitoring of disease progression.

Parkinson’s disease affects more than ten million people worldwide, and its numbers continue to climb as populations age. Yet the diagnosis remains stubbornly clinical, resting on the observation of motor symptoms such as tremor, rigidity, and slowness of movement. By the time those symptoms become obvious, a substantial fraction of the dopamine-producing neurons in the substantia nigra has already been lost, and no available therapy can restore them. Decades of research have made clear that Parkinson’s begins long before tremors appear, with disturbances in protein handling, mitochondrial function, inflammation, and metabolism unfolding across years or even decades. A reliable molecular readout of that process, drawn from an accessible body fluid, has been a long-standing goal of the field.

The new study addresses that goal through a targeted lens on the urinary metabolome. Rather than attempting to measure every small molecule in urine at once, the researchers focused on amines and phenols, two chemically related classes of compounds that include neurotransmitter breakdown products, microbial metabolites, and products of amino acid metabolism. To capture these molecules comprehensively, they used dansylation chemistry, a labeling technique in which dansyl chloride reacts with compounds bearing an amine or phenol group, attaching a fluorescent and easily ionizable tag to each one. This derivatization dramatically enhances the detectability of these compounds in liquid chromatography–mass spectrometry, boosting sensitivity, improving chromatographic separation, and suppressing interference from salts and other matrix components that normally complicate urine analysis.

The strategy allowed the team to profile thousands of tagged metabolite features in each urine sample with high reproducibility. Urine was collected from patients with Parkinson’s disease and from matched healthy controls, and the dansylated extracts were analyzed under standardized conditions. After rigorous preprocessing to align chromatographic peaks, remove noise, and normalize signal intensities across batches, the resulting data matrix captured the amine and phenol submetabolome of each participant in exquisite detail. Statistical and machine-learning approaches were then applied to identify the metabolite features that best discriminated patients from controls and to build predictive models capable of classifying new samples.

The analysis revealed a coherent disease signature rather than a scattering of random chemical differences. Among the compounds that shifted most consistently were metabolites tied to neurotransmitter metabolism, including products of the catecholamine pathways that are directly affected by the degeneration of dopaminergic circuits. Other discriminating features pointed to alterations in phenolic compounds, many of which originate in the gut, where microbial enzymes transform dietary constituents into phenols that are absorbed into the bloodstream and excreted by the kidneys. The involvement of these gut-derived molecules fits squarely within a growing body of evidence linking the intestinal microbiome to Parkinson’s disease, from changes in microbial composition reported in patient cohorts to the observation that gastrointestinal symptoms often precede motor onset by many years.

Beyond individual metabolites, the investigators examined the pathways in which the altered compounds participate. The results implicate disturbances in the metabolism of tyrosine and phenylalanine, the aromatic amino acids that serve as precursors to dopamine and to numerous phenolic products, as well as in tryptophan catabolism, which feeds both the serotonin and the kynurenine pathways and has been repeatedly connected to neurodegeneration and neuroinflammation. Shifts in these interconnected routes suggest that Parkinson’s disease is accompanied not by a single metabolic lesion but by a coordinated remodeling of how the body processes aromatic compounds, a remodeling that reflects the combined influence of the brain, the periphery, and the resident microbiota.

The translational payoff of the study lies in its biomarker candidates. Using feature-selection algorithms, the researchers distilled the thousands of measured variables down to a compact panel of metabolites that together classify samples with high accuracy in the discovery data and hold up under cross-validation. The panel’s performance was evaluated using standard metrics, including the area under the receiver operating characteristic curve, and the selected markers retained discriminative power when tested on independent sample sets. Enrichment analyses confirmed that the chosen compounds were not statistical artifacts but chemically meaningful indicators, clustering in the same metabolic pathways implicated by the broader dataset. A urine test built on such a panel could be repeated easily, costs little compared with imaging or cerebrospinal fluid analysis, and could in principle be deployed in clinics and community settings far beyond specialized movement disorder centers.

Methodological rigor underpins the credibility of these findings. Dansylated metabolomics is technically demanding, and the authors took extensive precautions to ensure that the observed differences reflected genuine biology rather than analytical drift. Internal standards were used to monitor derivatization efficiency, quality-control samples were interspersed throughout the analytical runs to track instrument stability, and batch effects were corrected statistically before group comparisons were made. Putative metabolite identifications were assigned with appropriate levels of confidence based on accurate mass, retention time, and comparison with labeled standards where available, following the community conventions for reporting metabolomics data. This attention to annotation standards matters, because it allows other laboratories to reproduce the measurements and to build on the reported signatures.

The study also carries implications for how Parkinson’s disease is understood at a systems level. Metabolomics sits at the downstream end of the biological information flow, integrating changes in genes, transcripts, proteins, and environment into a chemical readout of physiology. The urinary amine and phenol submetabolome, in particular, sits at the convergence of central neurotransmitter metabolism, peripheral amino acid handling, and gut microbial activity. Its alteration in Parkinson’s disease reinforces the view of the disorder as a multisystem condition in which the gut-brain axis and peripheral metabolism are active participants rather than bystanders. That perspective is already reshaping therapeutic thinking, with interventions targeting the microbiome, the enteric nervous system, and systemic metabolism joining the traditional focus on neurons of the substantia nigra.

Important caveats remain. The metabolic signature reported here was established in specific cohorts, and its generalizability across populations, disease stages, medications, diets, and comorbidities will need confirmation in large, prospective, multicenter studies. Levodopa therapy, which virtually all patients eventually receive, is itself a rich source of dopamine metabolites and must be carefully accounted for in any diagnostic application. Longitudinal data will be essential to determine whether the biomarker panel tracks disease progression, predicts conversion from prodromal states such as REM sleep behavior disorder, or responds to disease-modifying treatments once such treatments become available. Standardization of sample collection, storage, and processing across sites will likewise be critical before a urine-based test can enter routine practice.

Even so, the study represents a substantial step toward a long-elusive goal. It demonstrates that a chemically defined slice of the urinary metabolome, accessed through a well-established derivatization technique and interrogated with modern mass spectrometry and machine learning, carries enough disease-specific information to distinguish Parkinson’s patients from healthy controls with confidence. If validated at scale, the approach could complement emerging tools such as alpha-synuclein seed amplification assays and advanced imaging, offering a complementary, low-cost, and patient-friendly measure of the disease’s systemic chemistry. In a condition whose diagnosis currently depends on the arrival of irreversible motor damage, a simple urine test that reflects the underlying biology earlier would be a genuinely transformative addition to the clinical arsenal, and the present work provides a detailed molecular roadmap for building one.

Subject of Research: Urinary amine and phenol submetabolome profiling for Parkinson's disease biomarker discovery

Article Title: Decoding the metabolic landscape of Parkinson’s disease: dansylated urinary amines and phenols submetabolomes for signature profiling and biomarker discovery

Article References: Li, Z., Cui, P., Zhang, L., Huang, X., Zhou, Y., Xu, S., Mao, Y., Wang, Y., Liu, L., & Zhang, Y. (2026). Decoding the metabolic landscape of Parkinson’s disease: dansylated urinary amines and phenols submetabolomes for signature profiling and biomarker discovery. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01572-9

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01572-9

Keywords: Parkinson's disease, metabolomics, urinary biomarkers, dansylation, mass spectrometry, biomarker discovery, gut microbiome, neurodegeneration, dopamine metabolism, gut-brain axis, Decoding, metabolic